SCHEMBL22615

SCHEMBL22615

[c]1cccc2c1C(c1ccccc1)c1ccccc1O2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.42
LMNA P02545 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
MAPT P10636 3/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
ATM Q13315 2/20 0.39
NISCH Q9Y2I1 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40368 0.80 CYP2C9 (0.55) CYP2C9LMNAMEN1KMT2AMAPT
SCHEMBL5808750 0.79 MAOA (0.42) CYP2C9LMNAMEN1KMT2AMAPT
SCHEMBL8492933 0.77 MAOA (0.44) CYP2C9LMNAMEN1KMT2AMAPT
SCHEMBL521774 0.76 MAOA (0.62) CYP2C9LMNAMEN1KMT2AMAPT
SCHEMBL215606 0.74 LMNA (0.39) LMNAMAPTMAPK1ALDH1A1
SCHEMBL2716093 0.70 CYP2C9 (0.35) CYP2C9LMNAMEN1KMT2AMAPT
SCHEMBL292551 0.70 GRM1 (0.32)
SCHEMBL501810 0.69 GAA (0.65) CYP2C9LMNAMEN1KMT2AMAPT
Phosphine SCHEMBL23295992 0.68 GAA (0.63) CYP2C9LMNAMEN1KMT2AMAPT
SCHEMBL11781441 0.68 CYP2C9 (0.44) CYP2C9LMNAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932666-B2 Polymerizable compound, compound, and method for producing boranophosphate oligomer TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2024-03-19 US claimed
US-11897977-B2 Photolabile barbiturate compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2024-02-13 US claimed
US-20230108357-A1 Polymerizable Compound, Compound, and Method for Producing Boranophosphate Oligomer TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2023-04-06 US claimed
US-20220411790-A1 A CRISPR-CAS9 PLATFORM WITH AN INTRINSIC OFF-SWITCH AND ENHANCED SPECIFICITY THE JOHNS HOPKINS UNIVERSITY 2022-12-29 US claimed
US-11370940-B2 Adhesive article and methods of making and using the same 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-06-28 US claimed
CN-109937206-B Polymerizable compound, and method for producing borane phosphate oligomer 学校法人东京理科大学 2022-04-01 CN claimed
EP-3746489-B1 PHOTOLABILE BARBITURATE COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2022-03-30 EP claimed
US-20210277283-A1 ADHESIVE ARTICLE AND METHODS OF MAKING AND USING THE SAME 3M INNOVATIVE PROPERTIES COMPANY 2021-09-09 US claimed
CN-108348403-B Redox polymerizable compositions containing photolabile transition metal complexes 3M创新有限公司 2021-06-18 CN claimed
CN-108348404-B Redox polymerizable dental compositions utilizing photolabile transition metal complexes 3M创新有限公司 2021-06-08 CN claimed
US-20090131682-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2009-05-21 US claimed
US-20090093618-A1 STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM THE REGENTS OF THE UNIVERSITY OF CALIFORNA (US) 2009-04-09 US claimed
WO-2007131242-A2 STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-11-15 WO claimed
EP-0270651-B1 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES CALIFORNIA INST OF TECHN (US) 1994-06-15 EP claimed
US-5204456-A Derivatives of nucleosides and their use for the synthesis of oligonucleotides COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1993-04-20 US claimed
EP-0241363-B1 NUCLEOSIDE DERIVATIVES AND THEIR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1991-09-25 EP claimed
US-4849513-A Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1989-07-18 US claimed
EP-0270651-A4 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. CALIFORNIA INST OF TECHN (US) 1989-03-29 EP claimed
EP-0270651-A1 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. CALIFORNIA INST OF TECHN (US) 1988-06-15 EP claimed
WO-1988000201-A1 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) 1988-01-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932666-B2 Polymerizable compound, compound, and method for producing boranophosphate oligomer NR0B2, NR2E1, NR0B1 CYP2C9 4144/4885LMNA 869/4885MEN1 655/4885
US-20090093618-A1 STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM BTD, HLCS, SSB CYP2C9 4843/4885LMNA 3371/4885MEN1 1116/4885
US-20090131682-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS CYP2C9 3845/4885LMNA 1785/4885MEN1 1388/4885
US-11897977-B2 Photolabile barbiturate compounds PPOX, CBR1, CBR3 CYP2C9 265/4885LMNA 3594/4885MEN1 4096/4885
US-20230108357-A1 Polymerizable Compound, Compound, and Method for Producing Boranophosphate Oligomer NR0B2, NR2E1, NR0B1 CYP2C9 4144/4885LMNA 869/4885MEN1 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.